GlassScriptPhysician profile
Lynne Melchior
NPI 1811232481
$3,915.74
in general payments reported to CMS, 2019-2025
33 companies · $669 in 2025
The $669 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $1,209 · 2023: $1,016 · 2024: $915 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.90 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $471.22 | 2023-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $459.89 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $445.42 | 2021-2024 | Jardiance, Baqsimi, Lyumjev |
| Xeris Pharmaceuticals, INC. | $291.65 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $167.89 | 2022-2023 | |
| Amryt Pharma Holdings LTD | $162.71 | 2022-2023 | Mycapssa |
| Amgen INC. | $158.66 | 2022-2025 | Repatha, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.72 | 2022-2025 | Jardiance |
| Abbvie INC. | $98.74 | 2022-2023 | |
| Beta Bionics, INC. | $98.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $95.59 | 2022-2025 | |
| Medtronic, INC. | $78.94 | 2023-2024 | Minimed 780g, Minimed 770g |
| Ultragenyx Pharmaceutical INC. | $77.07 | 2022-2023 | |
| Abbott Laboratories | $76.27 | 2022-2023 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $63.86 | 2022-2024 | Crysvita |
| Dexcom, INC. | $62.50 | 2022-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $57.53 | 2022 | |
| Amneal Pharmaceuticals LLC | $53.28 | 2023-2024 | Unithroid |
| Corcept Therapeutics | $50.10 | 2021-2025 | Korlym |
| Amarin Pharma, INC. | $40.43 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $38.92 | 2023-2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $36.90 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $36.56 | 2024 | |
| Cequr Corporation | $31.52 | 2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $21.74 | 2022 | |
| Chiesi USA, INC. | $20.58 | 2024 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $20.44 | 2025 | |
| Avion Pharmaceuticals | $20.19 | 2023 | NP Thyroid 60 |
| Verity Pharmaceuticals INC. | $19.53 | 2024 | Tlando |
| Radius Health, INC. | $17.21 | 2024 | Tymlos |
| Rhythm Pharmaceuticals, INC. | $16.74 | 2025 | Imcivree |
| Zealand Pharma US, INC. | $14.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Melchior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.